Cargando…

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination

Despite dramatic advances in drug discovery over the decades, effective therapeutic strategies for cancers treatment are still in urgent demands. PROteolysis TArgeting Chimera (PROTAC), a novel therapeutic modality, has been vigorously promoted in preclinical and clinical applications. Unlike small...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Jinmei, Wu, Ye, Chen, Jinjiao, Shen, Yiwen, Zhang, Lijun, Zhang, Hong, Chen, Lili, Yuan, Hebao, Chen, Hongzhuan, Zhang, Weidong, Luan, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481416/ https://www.ncbi.nlm.nih.gov/pubmed/32929339 http://dx.doi.org/10.7150/thno.46985

Ejemplares similares

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins
por: Lin, Jiayi, et al.
Publicado: (2021)

Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer
por: Lu, Lu, et al.
Publicado: (2022)

Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer
por: Jin, Jinmei, et al.
Publicado: (2022)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Bruceine D inhibits HIF-1α-mediated glucose metabolism in hepatocellular carcinoma by blocking ICAT/β-catenin interaction
por: Huang, Rui, et al.
Publicado: (2021)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
por: Qi, Si-Min, et al.
Publicado: (2021)

Degradation of proteins by PROTACs and other strategies
por: Wang, Yang, et al.
Publicado: (2020)

Synthesis and biological evaluation of niclosamide PROTACs
por: Munoz, Erick, et al.
Publicado: (2022)

Small-Molecule PROTACs for Cancer Immunotherapy
por: Liu, Zefan, et al.
Publicado: (2022)

A PROTAC peptide induces durable β-catenin degradation and suppresses Wnt-dependent intestinal cancer
por: Liao, Hongwei, et al.
Publicado: (2020)

Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells
por: Wang, Mengge, et al.
Publicado: (2022)

PROTACs: A novel strategy for cancer drug discovery and development
por: Han, Xin, et al.
Publicado: (2023)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

Specific MHC-I Peptides Are Induced Using PROTACs
por: Jensen, Stephanie M., et al.
Publicado: (2018)

Designing Soluble PROTACs: Strategies and Preliminary Guidelines
por: García Jiménez, Diego, et al.
Publicado: (2022)

PROTAC: targeted drug strategy. Principles and limitations
por: Koroleva, O. A., et al.
Publicado: (2022)

Recent Advances in PROTAC-Based Antiviral Strategies
por: Ahmad, Haleema, et al.
Publicado: (2023)

Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
por: Yuan, Minghua, et al.
Publicado: (2021)

Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
por: Rana, Sandeep, et al.
Publicado: (2021)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs
por: Bai, Nan, et al.
Publicado: (2022)

Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation
por: Maniaci, Chiara, et al.
Publicado: (2017)

PROTACs for BRDs proteins in cancer therapy: a review
por: Wang, Chao, et al.
Publicado: (2022)

Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
por: Chen, Si, et al.
Publicado: (2022)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

Targeting Protein Kinases Degradation by PROTACs
por: Yu, Fei, et al.
Publicado: (2021)

An instructive attempt on developing aptamer-constructed PROTAC for breast cancer treatment
por: Zhang, Yuzhu, et al.
Publicado: (2022)

Editorial: Application of PROTACs as a Novel Strategy for Drug Discovery
por: Ibrahim, Hany S., et al.
Publicado: (2021)

Current strategies for the design of PROTAC linkers: a critical review
por: Troup, Robert I., et al.
Publicado: (2020)

PROTACs– a game-changing technology
por: Konstantinidou, Markella, et al.
Publicado: (2019)

De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy
por: Ma, Bohan, et al.
Publicado: (2022)

Light-induced control of protein destruction by opto-PROTAC
por: Liu, Jing, et al.
Publicado: (2020)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

Engineering exosomes as refined biological nanoplatforms for drug delivery
por: Luan, Xin, et al.
Publicado: (2017)

Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases
por: Luo, Xin, et al.
Publicado: (2022)

Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
por: Tamatam, Rekha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cihu599jl8c8la0ihivdt4paeh